Maintenance of clinical remission in early axial spondyloarthritis following certolizumab pegol dose reduction

BACKGROUND: The best strategy for maintaining clinical remission in patients with axial spondyloarthritis (axSpA) has not been defined. C-OPTIMISE compared dose continuation, reduction and withdrawal of the tumour necrosis factor inhibitor certolizumab pegol (CZP) following achievement of sustained...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Ann Rheum Dis
Asıl Yazarlar: Landewé, Robert BM, van der Heijde, Désirée, Dougados, Maxime, Baraliakos, Xenofon, Van den Bosch, Filip E, Gaffney, Karl, Bauer, Lars, Hoepken, Bengt, Davies, Owen R, de Peyrecave, Natasha, Thomas, Karen, Gensler, Lianne
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: BMJ Publishing Group 2020
Konular:
Spondyloarthritis
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7307216/
https://ncbi.nlm.nih.gov/pubmed/32381562
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/annrheumdis-2019-216839
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller